𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Kawasaki disease with exceptional cutaneous manifestations

✍ Scribed by Thierry Passeron; Valérie Olivier; Nicolas Sirvent; Ali Khalfi; Patrick Boutté; Jean-Philippe Lacour

Publisher
Springer
Year
2002
Tongue
English
Weight
141 KB
Volume
161
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Renal manifestations of Kawasaki's disea
Renal manifestations of Kawasaki's disease
✍ P. M. Nardi; J. O. Haller; A. P. Friedman; T. L. Slovis; R. M. Schaffer 📂 Article 📅 1985 🏛 Springer-Verlag 🌐 English ⚖ 524 KB
Undifferentiated connective tissue disea
Undifferentiated connective tissue disease and its cutaneous manifestations
✍ E Pestelli; W Volpi; B Giomi; M Caproni; P Fabbri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB

## ABSTRACT Undifferentiated connective tissue disease (UCTD, also named UCT syndrome, latent lupus or incomplete lupus) is regarded as an autoimmune disorder in which signs and symptoms are widely variable and evocative for connectivitis but not sufficiently evolved to fulfil any of the accepted c

Cholesterol crystal embolization: an ath
Cholesterol crystal embolization: an atherosclerotic disease with frequent and varied cutaneous manifestations
✍ KG Donohue; L Saap; V Falanga 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## ABSTRACT In this paper the basic pathogenesis of cholesterol crystal embolization (CCE) is described, its clinical characteristics are presented and diagnosis and therapy are discussed. The main focus will be on the cutaneous manifestations; however, considering that CCE is a systemic illness, f

The role of gabapentin in treating disea
The role of gabapentin in treating diseases with cutaneous manifestations and pain
✍ Noah Scheinfeld 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

## Abstract **Background** Gabapentin was first approved by the FDA in 1993 as an add‐on treatment for partial epileptic seizures. In May of 2002, it was approved as treatment for post‐herpetic neuralgia by the Food and Drug Adminstration. It appears to be a promising agent in the treatment of pain